Novartis AG (NVS) - צמיחת רווחי EPS רבעונית
Novartis AG stability across various jurisdictions shields it from geopolitical risks, as confirmed by the quarterly EPS comparison on the GURU.Markets base chart, where the -69.60 mark reflects the current state. Business efficiency relies on powerful research centers in the EU and US, while the implementation of AI in digital biology accelerates the release of new therapeutic agents.
%20%D7%A9%D7%99%D7%A0%D7%95%D7%99%20%D7%91%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_NVS_-_Novartis-AG_-_Year-over-year-net-earnings-per-share-change-for-the-last-twelve-months "NVS Novartis Corporation: צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים בטווח 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
פילוחי מדדים מקיפים ואנליטיקה עבור Novartis Pharma (NVS)
For the long-term investor, Novartis AG represents an asset with high potential for fundamental stability. Quarterly EPS growth measures the percentage change in net profit per share compared to the same period last year. By analyzing the current quarterly EPS growth rate, one can assess the effectiveness of the commercialization of innovative drugs for oncology and cardiology therapies. This indicator reflects the actual conversion of R&D successes into shareholder value. The stability of this metric confirms the viability of the company's business model.
